Roivant Sciences
Roivant is a biopharmaceutical company that utilizes a decentralized 'Vant' model to accelerate the development and commercialization of transformative medicines. The company advances a diverse pipeline of small molecules and biologics across immunology, inflammation, and pulmonary hypertension by creating nimble, subsidiary-focused business units. Beyond therapeutics, Roivant incubates discovery-stage companies and health technology startups to complement its core drug development engine.
Financials
Based on Q4 2026 filing
Revenue
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Biopharmaceutical Pipeline
primaryThe primary business focused on the clinical development and commercialization of drug candidates through specialized subsidiary companies known as Vants.
Brepocitinib, IMVT-1402, Batoclimab, Mosliciguat
Patients, Healthcare Providers, Pharmacy Benefit Managers
Technology & Discovery Platforms
moderateIncubation of health technology startups and discovery-stage entities that provide computational and logistical support for drug development and data management.
LNP Technology, VantAI, Lokavant, Datavant
Biopharmaceutical Companies, Clinical Research Organizations, Healthcare Data Analytics Firms
Segment Financials
Brepocitinib — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)
View metricMosliciguat — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)
View metricAnti-FcRn franchise—contractual costs related to batoclimab program discontinuation — Research and development (includes $47,867, $39,780 and $32,400 of share-based compensation expense for the years ended March 31, 2026, 2025 and 2024, respectively)
View metricOther development and discovery programs — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)
View metricReportable Segment — Acquired in-process research and development
View metricBusiness Overview
Competitive Position
Roivant maintains a unique position through its decentralized Vant model, which combines the focus of a biotech startup with the scale and resources of a large pharmaceutical firm.
Geographies
United States, European Union, United Kingdom, Japan
Customer Segments
Healthcare Providers, Pharmaceutical Companies, Government Health Programs
Upstream Dependencies
Academic Research Institutions, Contract Manufacturing Organizations, Contract Research Organizations, Pharmaceutical Licensors
Downstream Customers
Wholesale Distributors, Specialty Pharmacies, Hospitals, Government Payors
Competitors & Partners
Competitors
Similar Companies
Royalty Pharma
RPRX
Alnylam Pharmaceuticals
ALNY
Neurocrine Biosciences
NBIX
Incyte
INCY
Viatris
VTRS
Bristol-Myers Squibb
BMY
Biogen
BIIB
AbbVie
ABBV
Pfizer
PFE
Merck & Co.
MRK
Gilead Sciences
GILD
Johnson & Johnson
JNJ
IQVIA
IQV
Agilent Technologies
A
Guardant Health
GH
Vertex Pharmaceuticals
VRTX
Roper Technologies, Inc.
ROP
Cognizant
CTSH
Partners
Pfizer
PFE
Licensing partner for brepocitinib and ropsacitinib
HanAll Biopharma
Licensing partner for batoclimab and IMVT-1402
Samsung Biologics
Manufacturing and supply partner for batoclimab
Organon
OGN
Acquirer of Dermavant subsidiary
Sumitomo Pharma
Strategic alliance partner and acquirer of multiple Vants
Subsidiaries
Immunovant, Inc.
IMVT
Focused on autoimmune diseases
Priovant Therapeutics
Focused on autoimmune and inflammatory diseases
Pulmovant
Focused on pulmonary hypertension
Genevant Sciences
Focused on lipid nanoparticle (LNP) delivery technology
VantAI
Computational drug discovery platform
Lokavant
Clinical trial monitoring and data platform
Roivant Sciences FAQ
Common questions about Roivant Sciences
Roivant is a biopharmaceutical company that utilizes a decentralized 'Vant' model to accelerate the development and commercialization of transformative medicines. The company advances a diverse pipeline of small molecules and biologics across immunology, inflammation, and pulmonary hypertension by creating nimble, subsidiary-focused business units. Beyond therapeutics, Roivant incubates discovery-stage companies and health technology startups to complement its core drug development engine.
Roivant Sciences (ROIV) has a market capitalization of $21.6B and trades on NASDAQ.
Roivant Sciences generated $8.3M in trailing twelve-month revenue, with free cash flow of -$758.6M. These figures are based on the Q1 2026 filing.
Roivant Sciences's key competitors include Amgen, Moderna, Royalty Pharma plc Class A Ordinary Shares, and others. These companies compete in similar markets and product categories.
Roivant Sciences has approximately 908 employees.